Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Lung Cancer

  Free Subscription


1 AJR Am J Roentgenol
1 Am J Respir Crit Care Med
1 Ann Oncol
1 Ann Surg
4 Ann Surg Oncol
1 Ann Thorac Surg
5 Anticancer Res
1 Arch Bronconeumol
5 BMC Cancer
1 Br J Cancer
1 Cancer
2 Cancer Epidemiol Biomarkers Prev
2 Cancer Lett
1 Cancer Res
4 Cancer Sci
9 Chest
1 Clin Cancer Res
4 Clin Lung Cancer
1 Eur J Cardiothorac Surg
3 Int J Cancer
2 Int J Radiat Oncol Biol Phys
2 J Cancer Res Clin Oncol
1 J Clin Oncol
1 J Natl Cancer Inst
1 J Thorac Cardiovasc Surg
3 J Thorac Oncol
1 JAMA Oncol
3 Lancet Oncol
7 Lung Cancer
2 Oncogene
3 Oncol Rep
4 PLoS One
1 Proc Natl Acad Sci U S A

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    AJR Am J Roentgenol

    Editorial Comment: New Insights Into the MRI Diagnosis of Brain Metastasis From Lung Cancer.
    AJR Am J Roentgenol. 2021 Jun 2. doi: 10.2214/AJR.21.26288.

    Am J Respir Crit Care Med

    EHRs and Machine Learning for Early Detection of Lung Cancer and other Conditions: Thinking about the Path Ahead.
    Am J Respir Crit Care Med. 2021 Jun 7. doi: 10.1164/rccm.202104-1009.

    Ann Oncol

  3. RECK M, Carbone DP, Garassino M, Barlesi F, et al
    Targeting KRAS in non-small cell lung cancer: recent progress and new approaches.
    Ann Oncol. 2021 Jun 2. pii: S0923-7534(21)02045.
    PubMed         Abstract available

    Ann Surg

  4. YANKELEVITZ DF, Flores RM, Taioli E, Henschke CI, et al
    Is the Evidence for Thoracic Surgery of Early Stage Lung Cancer Adequate?
    Ann Surg. 2021 Jun 4. pii: 00000658-900000000-93524.

    Ann Surg Oncol

  5. CHIANG XH, Lin MW, Hsu HH, Chen JS, et al
    ASO Author Reflection: Comparing Wedge Resection and Segmentectomy as the Appropriate Surgical Method in cT1N0 Lung Cancer.
    Ann Surg Oncol. 2021 Jun 5. pii: 10.1245/s10434-021-10214.

  6. BATCHELOR T, Hasan J, Macbeth F, Shackcloth M, et al
    Randomised Controlled Trial Evidence Questions the Assumption that Pulmonary Metastasectomy Benefits Patients with Colorectal Cancer.
    Ann Surg Oncol. 2021 Feb 15. pii: 10.1245/s10434-020-09521.
    PubMed         Abstract available

  7. FU X, Wang F, Su X, Luo G, et al
    Endobronchial Ultrasound Improves Evaluation of Recurrent Laryngeal Nerve Lymph Nodes in Esophageal Squamous Cell Carcinoma Patients.
    Ann Surg Oncol. 2021;28:3930-3938.
    PubMed         Abstract available

  8. KIM IA, Hur JY, Kim HJ, Park JH, et al
    Targeted Next-Generation Sequencing Analysis for Recurrence in Early-Stage Lung Adenocarcinoma.
    Ann Surg Oncol. 2021;28:3983-3993.
    PubMed         Abstract available

    Ann Thorac Surg

  9. NOVELLIS P, Monaco F, Landoni G, Rossetti F, et al
    Venoarterial Extracorporeal Membrane Oxygenator Support in Lung Cancer Resection.
    Ann Thorac Surg. 2021 Jun 7. pii: S0003-4975(21)00998.
    PubMed         Abstract available

    Anticancer Res

  10. LIU YC, Hsu FT, Chung JG, Weng MC, et al
    Lenvatinib Induces AKT/NF-kappaB Inactivation, Apoptosis Signal Transduction and Growth Inhibition of Non-small Cell Lung Cancer In Vivo.
    Anticancer Res. 2021;41:2867-2874.
    PubMed         Abstract available

  11. KIM SY, Jeong EH, Lee TG, Kim HR, et al
    The Combination of Trametinib, a MEK Inhibitor, and Temsirolimus, an mTOR Inhibitor, Radiosensitizes Lung Cancer Cells.
    Anticancer Res. 2021;41:2885-2894.
    PubMed         Abstract available

  12. PUTRI HE, Sritularak B, Chanvorachote P
    DS-1 Inhibits Migration and Invasion of Non-small-cell Lung Cancer Cells Through Suppression of Epithelial to Mesenchymal Transition and Integrin beta1/FAK Signaling.
    Anticancer Res. 2021;41:2913-2923.
    PubMed         Abstract available

  13. MOHIUDDIN MD, Kasahara K
    Pemetrexed Disodium Heptahydrate Induces Apoptosis and Cell-cycle Arrest in Non-small-cell Lung Cancer Carrying an EGFR Exon 19 Deletion.
    Anticancer Res. 2021;41:2963-2977.
    PubMed         Abstract available

  14. LEE GD, Chung B, Song JS, Jang SJ, et al
    The Prognostic Value of Programmed Death-ligand 1 (PD-L1) in Patients who Received Neoadjuvant Chemoradiation Therapy Followed by Surgery for Locally Advanced Non-small Cell Lung Cancer.
    Anticancer Res. 2021;41:3193-3204.
    PubMed         Abstract available

    Arch Bronconeumol

  15. BORREGON RIVILLA M, Martinez Barroso K, Ramos Reguera I
    Severe Pulmonary Parenchymal Involvement Due to Reactivation of Latent Tuberculosis in a Patient With Small Cell Lung Cancer.
    Arch Bronconeumol. 2021 May 27. pii: S1579-2129(21)00169.

    BMC Cancer

  16. ZENG H, Yang Z, Li J, Wen Y, et al
    Associations between female lung cancer risk and sex steroid hormones: a systematic review and meta-analysis of the worldwide epidemiological evidence on endogenous and exogenous sex steroid hormones.
    BMC Cancer. 2021;21:690.
    PubMed         Abstract available

  17. CHEN C, Wu Z, Wu Z, Wu C, et al
    Therapeutic method for early-stage second primary non-small lung cancer: analysis of a population-based database.
    BMC Cancer. 2021;21:666.
    PubMed         Abstract available

  18. HUANG A, Xu Y, Zang X, Wu C, et al
    Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis.
    BMC Cancer. 2021;21:634.
    PubMed         Abstract available

  19. SHAN Q, Shi J, Wang X, Guo J, et al
    A new nomogram and risk classification system for predicting survival in small cell lung cancer patients diagnosed with brain metastasis: a large population-based study.
    BMC Cancer. 2021;21:640.
    PubMed         Abstract available

  20. ZHOU H, Li J, Chen Z, Chen Y, et al
    Nitric oxide in occurrence, progress and therapy of lung Cancer: a systemic review and meta-analysis.
    BMC Cancer. 2021;21:678.
    PubMed         Abstract available

    Br J Cancer

  21. WHITE MG, Schulte JJ, Xue L, Berger Y, et al
    Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy.
    Br J Cancer. 2021;124:564-566.
    PubMed         Abstract available


  22. PRINTZ C
    New findings show disparities in lung cancer care and research.
    Cancer. 2021;127:2173.

    Cancer Epidemiol Biomarkers Prev

  23. ZHANG EW, Shepard JO, Kuo A, Chintanapakdee W, et al
    Characteristics and outcomes of lung cancers detected on low-dose lung cancer screening CT.
    Cancer Epidemiol Biomarkers Prev. 2021 Jun 9. pii: 1055-9965.EPI-20-1847.
    PubMed         Abstract available

  24. ERHUNMWUNSEE L, Wing SE, Shen J, Hu H, et al
    The Association between Polluted Neighborhoods and TP53-Mutated Non-Small Cell Lung Cancer.
    Cancer Epidemiol Biomarkers Prev. 2021 Jun 4. pii: 1055-9965.EPI-20-1555.
    PubMed         Abstract available

    Cancer Lett

  25. JIANG ZB, Wang WJ, Xu C, Xie YJ, et al
    Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer.
    Cancer Lett. 2021;515:36-48.
    PubMed         Abstract available

  26. ZHANG J, Zeng Y, Xing Y, Li X, et al
    Myristoylation-mediated phase separation of EZH2 compartmentalizes STAT3 to promote lung cancer growth.
    Cancer Lett. 2021 Jun 5. pii: S0304-3835(21)00266.
    PubMed         Abstract available

    Cancer Res

  27. ISHIOKA K, Yasuda H, Hamamoto J, Terai H, et al
    Upregulation of fibroblast growth factor 9 in lung adenocarcinoma transdifferentiation to small cell lung cancer.
    Cancer Res. 2021 Jun 3. pii: 0008-5472.CAN-20-4048.
    PubMed         Abstract available

    Cancer Sci

  28. HE DH, Chen YF, Zhou YL, Zhang SB, et al
    Phytochemical library screen reveals betulinic acid as a novel Skp2-SCF E3 ligase inhibitor in non-small cell lung cancer.
    Cancer Sci. 2021 Jun 3. doi: 10.1111/cas.15005.
    PubMed         Abstract available

  29. TORIYAMA K, Takano N, Kokuba H, Kazama H, et al
    Azithromycin enhances the cytotoxicity of DNA-damaging drugs via lysosomal membrane permeabilization in lung cancer cells.
    Cancer Sci. 2021 May 29. doi: 10.1111/cas.14992.
    PubMed         Abstract available

  30. ARIYASU R, Uchibori K, Sasaki T, Tsukahara M, et al
    Monitoring epidermal growth factor receptor C797S mutation in Japanese non-small cell lung cancer patients with serial cell-free DNA evaluation using digital droplet PCR.
    Cancer Sci. 2021;112:2371-2380.
    PubMed         Abstract available

  31. SHUAI S, Liao X, Wang H, Liu L, et al
    TIP30 overcomes gefitinib resistance by regulating cytoplasmic and nuclear EGFR signaling in non-small cell lung cancer.
    Cancer Sci. 2021 May 31. doi: 10.1111/cas.15000.
    PubMed         Abstract available


  32. DUCOMB EA, Kinsey CM
    Chest. 2021;159:447-448.

  33. RAMAN V, Jawitz OK, D'Amico TA, Yang CJ, et al
    Chest. 2021;159:445-446.

  34. ABOUDARA M, Rickman OB, Maldonado F
    An Evaluation of Bronchoscopy Diagnostic Yield: Should We Only Be Doing EBUS?
    Chest. 2021;159:437-438.

  35. ALMQUIST DR, Sonbol MB, Ross HJ, Kosiorek H, et al
    Clinical Characteristics of Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia: A Retrospective Analysis.
    Chest. 2021;159:432-434.

  36. LEE HJ, Mazzone P, Feller-Kopman D, Yarmus L, et al
    Impact of the Percepta Genomic Classifier on Clinical Management Decisions in a Multicenter Prospective Study.
    Chest. 2021;159:401-412.
    PubMed         Abstract available

  37. MAYER N, Carboni GL, Thielken A, Wagnetz D, et al
    Sclerosing Pneumocytoma: A Host for a Typical Carcinoid With Pleural Metastasis-A Wolf in Sheep`s Clothing.
    Chest. 2021;159:e1-e5.
    PubMed         Abstract available

  38. ENDICOTT-YAZDANI TR, Baird RW, Koch MS, Moore AJ, et al
    A 55-Year-Old Woman With Frequent Pulmonary Exacerbations and Endobronchial Lesions.
    Chest. 2021;159:e49-e52.
    PubMed         Abstract available

    Differences in Staging and Treating Patients With Locally Advanced Non-small Cell Lung Cancer.
    Chest. 2021;159:2518-2519.

  40. ROY P, Fortin M
    Should We Expand Invasive Mediastinal Staging to Peripheral T1 Lung Tumors?
    Chest. 2021;159:446-447.

    Clin Cancer Res

  41. GARON EB, Spira AI, Johnson M, Bazhenova L, et al
    A phase 1b open-label, multicenter study of inhaled DV281, a TLR9 agonist, in combination with nivolumab in patients with advanced or metastatic non-small cell lung cancer.
    Clin Cancer Res. 2021 Jun 9. pii: 1078-0432.CCR-21-0263.
    PubMed         Abstract available

    Clin Lung Cancer

  42. OYANAGI J, Koh Y, Sato K, Teraoka S, et al
    Bloodborne Cytokines for Predicting Clinical Benefits and Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated With Anti-Programmed Cell Death 1 Inhibitors.
    Clin Lung Cancer. 2021 Apr 27. pii: S1525-7304(21)00091.
    PubMed         Abstract available

  43. MERKHOFER CM, Eaton KD, Martins RG, Ramsey SD, et al
    Impact of Clinical Trial Participation on Survival of Patients with Metastatic Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2021 Apr 22. pii: S1525-7304(21)00087.
    PubMed         Abstract available

  44. FISHER A, Kim S, Farhat D, Belzer K, et al
    Risk Factors Associated with a Second Primary Lung Cancer in Patients with an Initial Primary Lung Cancer.
    Clin Lung Cancer. 2021 Apr 23. pii: S1525-7304(21)00088.
    PubMed         Abstract available

  45. KOGURE Y, Hashimoto H, Oki M
    A Randomized Phase III Study of Pembrolizumab Versus Pembrolizumab-Carboplatin-Pemetrexed for Locally Advanced or Metastatic Nonsquamous Non-small-cell Lung Cancer with PD-L1 50% or more (LAPLACE-50): Study Protocol.
    Clin Lung Cancer. 2021 Feb 19. pii: S1525-7304(21)00031.
    PubMed         Abstract available

    Eur J Cardiothorac Surg

  46. FALCOZ PE, Olland A, Charloux A
    Does functional evaluation before lung cancer surgery need reappraisal?
    Eur J Cardiothorac Surg. 2021 Jun 11. pii: 6296136. doi: 10.1093.

    Int J Cancer

  47. DOMINE GOMEZ M, Csoszi T, Jaal J, Kudaba I, et al
    Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer.
    Int J Cancer. 2021 Jun 10. doi: 10.1002/ijc.33705.
    PubMed         Abstract available

  48. LILJEDAHL H, Karlsson A, Oskarsdottir GN, Salomonsson A, et al
    A gene expression-based single sample predictor of lung adenocarcinoma molecular subtype and prognosis.
    Int J Cancer. 2021;148:238-251.
    PubMed         Abstract available

  49. MU R, Liu H, Luo S, Patz EF Jr, et al
    Genetic variants of CHEK1, PRIM2 and CDK6 in the mitotic phase-related pathway are associated with nonsmall cell lung cancer survival.
    Int J Cancer. 2021 May 31. doi: 10.1002/ijc.33702.
    PubMed         Abstract available

    Int J Radiat Oncol Biol Phys

  50. YU F, Ni J, Zeng W, Zhou Y, et al
    Clinical value of upfront cranial radiotherapy in osimertinib-treated EGFR-mutant non-small-cell lung cancer with brain metastases.
    Int J Radiat Oncol Biol Phys. 2021 May 28. pii: S0360-3016(21)00667.
    PubMed         Abstract available

  51. SALAMA JK, Giuliani ME, Robinson CG, Daly ME, et al
    Single-fraction SBRT for Early Stage NSCLC-A Viable Option in "These Uncertain Times"?
    Int J Radiat Oncol Biol Phys. 2021;109:1-4.

    J Cancer Res Clin Oncol

  52. LIU J, Hao J, Niu Y, Wu X, et al
    Network pharmacology-based and clinically relevant prediction of active ingredients and potential targets of Chinese herbs on stage IV lung adenocarcinoma patients.
    J Cancer Res Clin Oncol. 2021;147:2079-2092.
    PubMed         Abstract available

  53. HE X, Ma X, Wang C, Luan M, et al
    The peptide mimicking small extracellular ring domain of CD82 inhibits tumor cell migration in vitro and metastasis in vivo.
    J Cancer Res Clin Oncol. 2021;147:1927-1934.
    PubMed         Abstract available

    J Clin Oncol

  54. REMON J, Hendriks LEL, Besse B
    Paving the Way for Long-Term Survival in Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2021 Jun 8:JCO2100760. doi: 10.1200/JCO.21.00760.

    J Natl Cancer Inst

  55. WANG X, Ricciuti B, Alessi JV, Nguyen T, et al
    Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer.
    J Natl Cancer Inst. 2021 Jun 11. pii: 6296846. doi: 10.1093.
    PubMed         Abstract available

    J Thorac Cardiovasc Surg

    Commentary: Why do we operate in metastatic lung cancer?
    J Thorac Cardiovasc Surg. 2021 May 8. pii: S0022-5223(21)00771.

    J Thorac Oncol

  57. JAZIEH AR, Onal HC, Weng Tan DS, Soo RA, et al
    Real-world treatment patterns and clinical outcomes in patients with stage III non-small cell lung cancer: Results of KINDLE, a multi-country observational study.
    J Thorac Oncol. 2021 May 26. pii: S1556-0864(21)02174.
    PubMed         Abstract available

  58. AKAMATSU H, Murakami H, Harada H, Shimizu J, et al
    Gefitinib with concurrent thoracic radiotherapy in unresectable locally advanced non-small cell lung cancer with EGFR mutation; West Japan Oncology Group 6911L.
    J Thorac Oncol. 2021 Jun 8. pii: S1556-0864(21)02190.
    PubMed         Abstract available

  59. SU CC, Wu JT, Neal JW, Popat RA, et al
    Impact of Low-Dose CT Screening for Primary Lung Cancer on Subsequent Risk of Brain Metastasis.
    J Thorac Oncol. 2021 Jun 3. pii: S1556-0864(21)02181.
    PubMed         Abstract available

    JAMA Oncol

  60. JABBOUR SK, Lee KH, Frost N, Breder V, et al
    Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial.
    JAMA Oncol. 2021 Jun 4. pii: 2780855. doi: 10.1001/jamaoncol.2021.2301.
    PubMed         Abstract available

    Lancet Oncol

  61. GRONBERG BH, Langer SW, Nyman J, Halvorsen TO, et al
    Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer - Authors' reply.
    Lancet Oncol. 2021;22:e222.

  62. XIE L, Fan X, Qian B
    Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer.
    Lancet Oncol. 2021;22:e221.

  63. LEVY A, Le Pechoux C, Faivre-Finn C
    Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer.
    Lancet Oncol. 2021;22:e220.

    Lung Cancer

  64. HE LN, Fu S, Zhang X, Hu Q, et al
    Baseline and early changes in circulating Serum Amyloid A (SAA) predict survival outcomes in advanced non-small cell lung cancer patients treated with Anti-PD-1/PD-L1 monotherapy.
    Lung Cancer. 2021;158:1-8.
    PubMed         Abstract available

  65. GRIESINGER F, Eberhardt W, Nusch A, Reiser M, et al
    Corrigendum to "Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP registry (AIO-TRK-0315)" [Lung Cancer 152 (2021) 174-184].
    Lung Cancer. 2021;157:167.

  66. POPAT S, Brustugun OT, Cadranel J, Felip E, et al
    Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer.
    Lung Cancer. 2021;157:9-16.
    PubMed         Abstract available

  67. FUNG AS, Graham DM, Chen EX, Stockley TL, et al
    A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer.
    Lung Cancer. 2021;157:21-29.
    PubMed         Abstract available

  68. LIU R, Ota K, Iwama E, Yoneshima Y, et al
    Quantification of HER family dimers by proximity ligation assay and its clinical evaluation in non-small cell lung cancer patients treated with osimertinib.
    Lung Cancer. 2021 May 25. pii: S0169-5002(21)00403.
    PubMed         Abstract available

  69. SATO T, Shimada Y, Mimae T, Tsutani Y, et al
    The impact of pathological lymph node metastasis with lymphatic invasion on the survival of patients with clinically node-negative non-small cell lung cancer: A multicenter study.
    Lung Cancer. 2021;158:9-14.
    PubMed         Abstract available

  70. DI STASIO GD, Travascio L, Colandrea M, Spaggiari L, et al
    Prognostic value of PET parameters in patients with pleomorphic lung cancer: Results from a single institution.
    Lung Cancer. 2021;158:40-46.
    PubMed         Abstract available


  71. YANG X, Chen Y, Zhou Y, Wu C, et al
    GPC5 suppresses lung cancer progression and metastasis via intracellular CTDSP1/AhR/ARNT signaling axis and extracellular exosome secretion.
    Oncogene. 2021 Jun 2. pii: 10.1038/s41388-021-01837.
    PubMed         Abstract available

  72. LIU W, Huang Y, Wang D, Han F, et al
    MPDZ as a novel epigenetic silenced tumor suppressor inhibits growth and progression of lung cancer through the Hippo-YAP pathway.
    Oncogene. 2021 Jun 9. pii: 10.1038/s41388-021-01857.
    PubMed         Abstract available

    Oncol Rep

  73. ZINNAH KMA, Park SY
    Sensitizing TRAILresistant A549 lung cancer cells and enhancing TRAILinduced apoptosis with the antidepressant amitriptyline.
    Oncol Rep. 2021;46.
    PubMed         Abstract available

  74. ZENG T, Xu M, Zhang W, Gu X, et al
    Autophagy inhibition and microRNA199a5p upregulation in paclitaxelresistant A549/T lung cancer cells.
    Oncol Rep. 2021;46.
    PubMed         Abstract available

  75. KIM MK, Choi MJ, Lee HM, Choi HS, et al
    Heterogeneous nuclear ribonucleoprotein A2/B1 regulates the ERK and p53/HDM2 signaling pathways to promote the survival, proliferation and migration of nonsmall cell lung cancer cells.
    Oncol Rep. 2021;46.
    PubMed         Abstract available

    PLoS One

  76. BARATA F, Fidalgo P, Figueiredo S, Tonin FS, et al
    Limitations and perceived delays for diagnosis and staging of lung cancer in Portugal: A nationwide survey analysis.
    PLoS One. 2021;16:e0252529.
    PubMed         Abstract available

  77. STEFANI D, Hegedues B, Collaud S, Zaatar M, et al
    Torque Teno Virus load in lung cancer patients correlates with age but not with tumor stage.
    PLoS One. 2021;16:e0252304.
    PubMed         Abstract available

  78. FRANCO F, Carcereny E, Guirado M, Ortega AL, et al
    Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry.
    PLoS One. 2021;16:e0251761.
    PubMed         Abstract available

  79. ROUNIS K, Makrakis D, Papadaki C, Monastirioti A, et al
    Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study.
    PLoS One. 2021;16:e0252537.
    PubMed         Abstract available

    Proc Natl Acad Sci U S A

  80. CHIBAYA L, Karim B, Zhang H, Jones SN, et al
    Mdm2 phosphorylation by Akt regulates the p53 response to oxidative stress to promote cell proliferation and tumorigenesis.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.